L L Ilag
Overview
Explore the profile of L L Ilag including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
791
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malone J, Anderson J, Wolpert H, Ilag L, Frank B, De Felippis M, et al.
Pediatr Endocrinol Rev
. 2020 Mar;
17(Suppl 1):138-160.
PMID: 32208559
Eli Lilly and Company has played a pivotal role in the development of insulin products since its discovery in 1921. Through their dedication to pharmaceutical innovation, Josiah K. Lilly Sr....
2.
Cummings M, Cao D, Hadjiyianni I, Ilag L, Tan M
Clin Diabetes Endocrinol
. 2018 May;
4:10.
PMID: 29760944
Background: To identify baseline/clinical characteristics associated with clinically meaningful responses to insulin glargine 100 U/mL (IGlar) in insulin-naive people with type 2 diabetes mellitus (T2DM). Methods: Individual participant data were...
3.
Hadjiyianni I, Dahl D, Lacaya L, Pollom R, Chang C, Ilag L
Diabetes Obes Metab
. 2016 Jan;
18(4):425-9.
PMID: 26749289
The safety and efficacy of LY2963016 insulin glargine (LY IGlar) and Lantus insulin glargine (IGlar), products with identical primary amino acid sequences, were assessed in subgroups of patients with type...
4.
Ilag L, Deeg M, Costigan T, Hollander P, Blevins T, Edelman S, et al.
Diabetes Obes Metab
. 2015 Oct;
18(2):159-68.
PMID: 26434665
Aims: To compare the immunogenicity profiles and the potential effects on clinical outcomes of LY2963016 insulin glargine (LY IGlar) and Lantus® insulin glargine (IGlar), products with identical primary amino acid...
5.
Blevins T, Dahl D, Rosenstock J, Ilag L, Huster W, Zielonka J, et al.
Diabetes Obes Metab
. 2015 May;
17(8):726-33.
PMID: 25974640
Aims: To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) and the reference product (Lantus®) insulin glargine (IGlar) in patients with type 1 diabetes (T1D). Methods: This...
6.
Rosenstock J, Hollander P, Bhargava A, Ilag L, Pollom R, Zielonka J, et al.
Diabetes Obes Metab
. 2015 May;
17(8):734-41.
PMID: 25931141
Aims: To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) and the reference product (Lantus(®)) insulin glargine (IGlar) in combination with oral antihyperglycaemic medications in patients with...
7.
Jain S, Mao X, Escalante-Pulido M, Vorokhobina N, Lopez I, Ilag L
Diabetes Obes Metab
. 2010 Oct;
12(11):967-75.
PMID: 20880343
Aims: To compare two progressive approaches [once-daily insulin glargine plus ≤3 mealtime lispro (G+L) vs. insulin lispro mix 50/50 (LM50/50) progression once up to thrice daily (premix progression, PP)] of...
8.
Sarwat S, Ilag L, Carey M, Shrom D, Heine R
Diabet Med
. 2010 Jun;
27(5):589-92.
PMID: 20536957
Aims: Self-monitoring of blood glucose (SMBG) is an important self-management tool for insulin-treated patients with Type 2 diabetes mellitus (T2DM). Its value in estimating glycaemic control in insulin-treated T2DM patients...
9.
Chacra A, Kipnes M, Ilag L, Sarwat S, Giaconia J, Chan J
Diabet Med
. 2010 Jun;
27(5):563-9.
PMID: 20536953
Aims: The efficacy of two basal insulins, insulin lispro protamine suspension (ILPS) and insulin detemir, was compared in basal-bolus regimens in Type 1 diabetes. Methods: In this 32-week, multinational, parallel-group,...
10.
Bagci T, Wu J, Pfannl R, Ilag L, Jay D
Oncogene
. 2009 Aug;
28(40):3537-50.
PMID: 19684614
Glioblastoma multiforme (GBM) is the most malignant glioma type with diffuse borders due to extensive tumor cell infiltration. Therefore, understanding the mechanism of GBM cell dispersal is critical for developing...